scholarly journals Chromium: Rise and Shine in Peritoneal Dialysis Patients?

2019 ◽  
Vol 39 (4) ◽  
pp. 320-322
Author(s):  
Guido Filler ◽  
Christopher McIntyre
Keyword(s):  
Trace Elements ◽  
Peritoneal Dialysis ◽  
Selenium Deficiency ◽  
Cross Sectional Study ◽  
Chromium Concentration ◽  
Feed Water ◽  
Dialysis Patients ◽  
Cross Sectional ◽  
Spent Dialysate ◽  
Beneficial Outcome

Some trace elements are altered with chronic kidney disease. Selenium, zinc, and manganese tend to be wasted, and there is growing evidence that selenium deficiency is associated with mortality on dialysis. Other trace elements accumulate, such as chromium, cobalt, lead, molybdenum, and vanadium. The highest chromium levels are found in dialysis patients. The dialysis modality may further affect these levels, especially in hemodialysis patients, where even small contaminations in the dialysis feed water may lead to a concentration gradient that increases the concentration of certain trace elements. Chromium levels in peritoneal dialysis (PD) patients have been understudied. A single cross-sectional study found substantially higher chromium levels in PD patients. In that study, the chromium concentration in the spent dialysate decreased substantially, suggesting that PD fluid could be a source of chromium. Chromium-lactate complexes may have been formed, which are easily absorbed. In our center, we observed a decrease in chromium level when using physiological PD fluids. This review discusses the potential mechanisms and raises the question of whether this accumulation of chromium is unlikely to be associated with a beneficial outcome.

Sevelamer Hydrochloride in Peritoneal Dialysis Patients: Results of a Multicenter Cross-Sectional Study

2007 ◽  
Vol 27 (6) ◽  
pp. 697-701 ◽  
Author(s):  
Rosa Ramos ◽  
Francesc Moreso ◽  
Mercè Borras ◽  
Esther Ponz ◽  
Joan M. Buades ◽  
...  
Keyword(s):  
Peritoneal Dialysis ◽  
Ldl Cholesterol ◽  
Density Lipoprotein ◽  
Cross Sectional Study ◽  
Serum Phosphate ◽  
Sectional Study ◽  
C Reactive Protein ◽  
Dialysis Patients ◽  
Cross Sectional ◽  
Reactive Protein

Background Sevelamer hydrochloride is a phosphate binder widely employed in hemodialysis patients. Until now, information about its efficacy and safety in peritoneal dialysis patients has been scarce. Patients and Methods In September 2005 a cross-sectional study of demographic, biochemical, and therapeutic data of patients from 10 peritoneal dialysis units in Catalonia and the Balearic Islands, Spain, was conducted. Results We analyzed data from 228 patients. At the time of the study, 128 patients (56%) were receiving sevelamer. Patients receiving sevelamer were younger ( p < 0.01), showed a longer period of time on dialysis ( p < 0.01), and had a lower Charlson Comorbidity Index ( p < 0.01). Serum calcium and intact parathyroid hormone levels were not different between the two groups, while phosphate levels <5.5 mg/dL were observed more frequently in patients not receiving sevelamer (79% vs 61%, p < 0.01). Serum total cholesterol (167 ± 41 vs 189 ± 42 mg/dL, p < 0.01) and low density lipoprotein (LDL) cholesterol (90 ± 34 vs 109 ± 34 mg/dL, p < 0.01), but not high density lipoprotein cholesterol or triglycerides, were lower in sevelamer-treated patients. Moreover, sevelamer-treated patients displayed a higher serum albumin (38 ± 5 vs 36 ± 4 g/L, p < 0.01) and a lower C-reactive protein (4.9 ± 12.8 vs 8.8 ± 15.7 mg/L, p < 0.01). Blood bicarbonate levels <22 mmol/L were observed more frequently in patients receiving sevelamer (22% vs 5%, p < 0.01). Logistic regression analysis adjusting by confounding variables confirmed that sevelamer therapy was associated with serum total cholesterol <200 mg/dL [relative risk (RR): 2.77, 95% confidence interval (CI): 1.44 – 5.26, p = 0.002] and blood bicarbonate <22 mmol/L (RR: 8.5, 95% CI: 2.6 – 27.0, p < 0.001), but not with serum phosphate >5.5 mg/dL, calcium–phosphate product >55 mg2/dL2, serum albumin <35 g/L, or C-reactive protein >5 mg/L. Conclusions This uncontrolled cross-sectional study in peritoneal dialysis patients showed that sevelamer hydro-chloride treatment allows an adequate serum phosphate level in about 60% of patients and significantly reduces total and LDL-cholesterol levels. Since this treatment is associated with metabolic acidosis in 22% of patients, we recommend close monitoring of bicarbonate levels in this group of patients until the clinical significance of this result is clarified.

scholarly journals A Cross-sectional Study of Fixed and Growth Mindset in Adult Peritoneal Dialysis Patients

2021 ◽  
Vol 8 ◽  
pp. 237437352110552
Author(s):  
Rachel B. Fissell ◽  
David Schlundt ◽  
Kerri L. Cavanaugh ◽  
Claudia Mueller ◽  
Ebele M. Umeukeje ◽  
...  
Keyword(s):  
Peritoneal Dialysis ◽  
Self Efficacy ◽  
Convergent Validity ◽  
Cross Sectional Study ◽  
Growth Mindset ◽  
Dialysis Patients ◽  
Cross Sectional ◽  
Home Dialysis ◽  
Targeted Interventions ◽  
New Strategies

Increasing home dialysis prevalence is an international priority. Many patients start peritoneal dialysis, then transition to hemodialysis after complications. New strategies are needed to support modality persistence. Health mindset refers to individual belief about capacity to change to improve health. Mindset was measured in a cross-section of 101 adult peritoneal dialysis patients from April 2019 to June 2020. The Health Mindset Scale was administered to characterize the continuum of fixed vs. growth mindset with respect to health. Health literacy and health self-efficacy were also assessed. Participants were 43% female, 32% African American, and 42% diabetic. Health mindset scores were skewed toward growth (range 3–18), with average (SD) 12.83 (4.2). Growth mindset was strongly associated with health self-efficacy. Adults receiving peritoneal dialysis report health mindset variation. Growth mindset and health self-efficacy correlation suggests measurement of similar constructs, demonstrating convergent validity. The Health Mindset Scale may identify individuals who could benefit from targeted interventions to improve mindset, and foster peritoneal dialysis modality persistence.

Fatigue in Peritoneal Dialysis Patients and an Exploration of Contributing Factors: A Cross-Sectional Study

2020 ◽  
Vol 59 (5) ◽  
pp. 1074-1081.e2
Author(s):  
Chong Tian ◽  
Beibei Zhang ◽  
Wangqun Liang ◽  
Qing Yang ◽  
Qianqian Xiong ◽  
...  
Keyword(s):  
Peritoneal Dialysis ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Dialysis Patients ◽  
Contributing Factors ◽  
Cross Sectional
Sign in / Sign up

Export Citation Format

Share Document